Back
~
1
min read
· Posted on
February 21, 2024

Johnson & Johnson just got a big, juicy, $17bn heart

Johnson & Johnson just acquired a new heart device maker.

What's the key learning?

  • Johnson & Johnson acquired heart device maker Abiomed in a deal worth $17 billion USD.
  • Johnson & Johnson will have to fork out 51% more than Abiomed's share price before the deal was announced, but they will enjoy Abiomed's $1 billion in annual revenue.
  • Heart disease is the leading cause of death globally so it makes sense to allocate capital to a heart disease treatment.

👉 Background: Johnson & Johnson was founded in 1886, and it develops medical devices, pharmaceuticals, and consumer goods. It is one of the world's most valuable companies, worth around $446b USD.

👉 What happened: Last year, Johnson & Johnson decided to sell its consumer division to go all-in on its other business areas, including medical devices. And now, it’s acquired Abiomed, a heart device maker, in a deal worth around $17 billion USD.

👉 What else: Johnson & Johnson will have to fork out 51% more than Abiomed’s share price before the deal was announced - but they will enjoy Abiomed’s $1 billion in annual revenue.

What's the key learning?

💡Start preparing for your next feast - right after your last. Johnson & Johnson is well and truly flush with cash right now thanks to its COVID vaccine sales.

💡 As a result, Johnson & Johnson can afford to buy other companies… especially while valuations are relatively low. Heart disease is the leading cause of death globally so it makes sense to allocate capital to a heart disease treatment.

💡And they aren’t the only ones. Johnson & Johnson’s rival Pfizer (also flush with cash), plans to launch 19 new products over the next 18 months.

Ready to win at money?

Sign up for Flux and join 100,000 members of the Flux family

A button to App StoreGoogle Play store button
Excellent  4.9 out of 5
Star rating
No items found.